Cargando…

TCMIP v2.0 Powers the Identification of Chemical Constituents Available in Xinglou Chengqi Decoction and the Exploration of Pharmacological Mechanisms Acting on Stroke Complicated With Tanre Fushi Syndrome

Xinglou Chengqi (XLCQ) decoction, composed of three botanical drugs and one inorganic drug, is used in clinics during the treatment of acute stroke complicated with Tanre Fushi (TRFS) syndrome in China. However, its active ingredients and the molecular mechanism have not been clarified. So, we aimed...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Ping, Wang, Shuang, Chen, Hong, Deng, Xiaofang, Zhang, Luoqi, Xu, Haiyu, Yang, Hongjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8320350/
https://www.ncbi.nlm.nih.gov/pubmed/34335236
http://dx.doi.org/10.3389/fphar.2021.598200
_version_ 1783730631784529920
author Wang, Ping
Wang, Shuang
Chen, Hong
Deng, Xiaofang
Zhang, Luoqi
Xu, Haiyu
Yang, Hongjun
author_facet Wang, Ping
Wang, Shuang
Chen, Hong
Deng, Xiaofang
Zhang, Luoqi
Xu, Haiyu
Yang, Hongjun
author_sort Wang, Ping
collection PubMed
description Xinglou Chengqi (XLCQ) decoction, composed of three botanical drugs and one inorganic drug, is used in clinics during the treatment of acute stroke complicated with Tanre Fushi (TRFS) syndrome in China. However, its active ingredients and the molecular mechanism have not been clarified. So, we aimed to preliminarily characterize its chemical constituents and investigate its pharmacological mechanisms using an integrative pharmacology strategy, including component analysis, network prediction, and experimental verification. We employed UPLC-QTOF-MS/MS to describe the chemical profile of XLCQ, Integrative Pharmacology-based Network Computational Research Platform of Traditional Chinese Medicine (TCMIP v2.0, http://www.tcmip.cn/), to assist in identifying the chemical components and predict the putative molecular mechanism against acute stroke complicated with TRFS, and LPS-stimulated BV-2 cells to verify the anti-neuroinflammatory effects of luteolin, apigenin, and chrysoeriol. Altogether, 197 chemical compounds were identified or tentatively characterized in the water extraction of XLCQ, 22 of them were selected as the key active constituents that may improve the pathological state by regulating 27 corresponding targets that are mainly involved in inflammation/immune-related pathways, and furthermore, luteolin, apigenin, and chrysoeriol exhibited good anti-neuroinflammatory effects from both protein and mRNA levels. In summary, it is the first time to employ an integrative pharmacology strategy to delineate 22 constituents that may improve the pathological state of stroke with TRFS by regulating 27 corresponding targets, which may offer a highly efficient way to mine the scientific connotation of traditional Chinese medicine prescriptions. This study might be a supplement for the deficiency of the basic research of XLCQ.
format Online
Article
Text
id pubmed-8320350
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-83203502021-07-30 TCMIP v2.0 Powers the Identification of Chemical Constituents Available in Xinglou Chengqi Decoction and the Exploration of Pharmacological Mechanisms Acting on Stroke Complicated With Tanre Fushi Syndrome Wang, Ping Wang, Shuang Chen, Hong Deng, Xiaofang Zhang, Luoqi Xu, Haiyu Yang, Hongjun Front Pharmacol Pharmacology Xinglou Chengqi (XLCQ) decoction, composed of three botanical drugs and one inorganic drug, is used in clinics during the treatment of acute stroke complicated with Tanre Fushi (TRFS) syndrome in China. However, its active ingredients and the molecular mechanism have not been clarified. So, we aimed to preliminarily characterize its chemical constituents and investigate its pharmacological mechanisms using an integrative pharmacology strategy, including component analysis, network prediction, and experimental verification. We employed UPLC-QTOF-MS/MS to describe the chemical profile of XLCQ, Integrative Pharmacology-based Network Computational Research Platform of Traditional Chinese Medicine (TCMIP v2.0, http://www.tcmip.cn/), to assist in identifying the chemical components and predict the putative molecular mechanism against acute stroke complicated with TRFS, and LPS-stimulated BV-2 cells to verify the anti-neuroinflammatory effects of luteolin, apigenin, and chrysoeriol. Altogether, 197 chemical compounds were identified or tentatively characterized in the water extraction of XLCQ, 22 of them were selected as the key active constituents that may improve the pathological state by regulating 27 corresponding targets that are mainly involved in inflammation/immune-related pathways, and furthermore, luteolin, apigenin, and chrysoeriol exhibited good anti-neuroinflammatory effects from both protein and mRNA levels. In summary, it is the first time to employ an integrative pharmacology strategy to delineate 22 constituents that may improve the pathological state of stroke with TRFS by regulating 27 corresponding targets, which may offer a highly efficient way to mine the scientific connotation of traditional Chinese medicine prescriptions. This study might be a supplement for the deficiency of the basic research of XLCQ. Frontiers Media S.A. 2021-07-15 /pmc/articles/PMC8320350/ /pubmed/34335236 http://dx.doi.org/10.3389/fphar.2021.598200 Text en Copyright © 2021 Wang, Wang, Chen, Deng, Zhang, Xu and Yang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Wang, Ping
Wang, Shuang
Chen, Hong
Deng, Xiaofang
Zhang, Luoqi
Xu, Haiyu
Yang, Hongjun
TCMIP v2.0 Powers the Identification of Chemical Constituents Available in Xinglou Chengqi Decoction and the Exploration of Pharmacological Mechanisms Acting on Stroke Complicated With Tanre Fushi Syndrome
title TCMIP v2.0 Powers the Identification of Chemical Constituents Available in Xinglou Chengqi Decoction and the Exploration of Pharmacological Mechanisms Acting on Stroke Complicated With Tanre Fushi Syndrome
title_full TCMIP v2.0 Powers the Identification of Chemical Constituents Available in Xinglou Chengqi Decoction and the Exploration of Pharmacological Mechanisms Acting on Stroke Complicated With Tanre Fushi Syndrome
title_fullStr TCMIP v2.0 Powers the Identification of Chemical Constituents Available in Xinglou Chengqi Decoction and the Exploration of Pharmacological Mechanisms Acting on Stroke Complicated With Tanre Fushi Syndrome
title_full_unstemmed TCMIP v2.0 Powers the Identification of Chemical Constituents Available in Xinglou Chengqi Decoction and the Exploration of Pharmacological Mechanisms Acting on Stroke Complicated With Tanre Fushi Syndrome
title_short TCMIP v2.0 Powers the Identification of Chemical Constituents Available in Xinglou Chengqi Decoction and the Exploration of Pharmacological Mechanisms Acting on Stroke Complicated With Tanre Fushi Syndrome
title_sort tcmip v2.0 powers the identification of chemical constituents available in xinglou chengqi decoction and the exploration of pharmacological mechanisms acting on stroke complicated with tanre fushi syndrome
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8320350/
https://www.ncbi.nlm.nih.gov/pubmed/34335236
http://dx.doi.org/10.3389/fphar.2021.598200
work_keys_str_mv AT wangping tcmipv20powerstheidentificationofchemicalconstituentsavailableinxinglouchengqidecoctionandtheexplorationofpharmacologicalmechanismsactingonstrokecomplicatedwithtanrefushisyndrome
AT wangshuang tcmipv20powerstheidentificationofchemicalconstituentsavailableinxinglouchengqidecoctionandtheexplorationofpharmacologicalmechanismsactingonstrokecomplicatedwithtanrefushisyndrome
AT chenhong tcmipv20powerstheidentificationofchemicalconstituentsavailableinxinglouchengqidecoctionandtheexplorationofpharmacologicalmechanismsactingonstrokecomplicatedwithtanrefushisyndrome
AT dengxiaofang tcmipv20powerstheidentificationofchemicalconstituentsavailableinxinglouchengqidecoctionandtheexplorationofpharmacologicalmechanismsactingonstrokecomplicatedwithtanrefushisyndrome
AT zhangluoqi tcmipv20powerstheidentificationofchemicalconstituentsavailableinxinglouchengqidecoctionandtheexplorationofpharmacologicalmechanismsactingonstrokecomplicatedwithtanrefushisyndrome
AT xuhaiyu tcmipv20powerstheidentificationofchemicalconstituentsavailableinxinglouchengqidecoctionandtheexplorationofpharmacologicalmechanismsactingonstrokecomplicatedwithtanrefushisyndrome
AT yanghongjun tcmipv20powerstheidentificationofchemicalconstituentsavailableinxinglouchengqidecoctionandtheexplorationofpharmacologicalmechanismsactingonstrokecomplicatedwithtanrefushisyndrome